IL6 and breast carcinoma: In agreement with these observations, IL6 treatment of ER expressing breast cancer cells (MCF7, T47D) led to a reduction in ER protein expression, ER promoter-driven luciferase and oestrogen response element (ERE)-dependent transcription, which were reversed with tocilizumab (Supplementary Fig. 2f,g).